Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
about
Oncolytic virus therapy: A new era of cancer treatment at dawnThe Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) ProteinRapid and sensitive lentivirus vector-based conditional gene expression assay to monitor and quantify cell fusion activityMicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropismCombination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer.Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.A Double-Switch Cell Fusion-Inducible Transgene Expression System for Neural Stem Cell-Based Antiglioma Gene Therapy.TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer.Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytiaMeasles virus for cancer therapy.Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents.Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon.A third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice.
P2860
Q26739714-87F70063-97C3-40A9-A7C0-816E003CA236Q28069519-61AD59E8-F087-48A3-A14B-520FFCAF2A75Q28474202-209D58AB-2A96-408D-B3A7-4F68598A8532Q30502129-7CFB51C6-BE6A-43B1-B5FC-87909A979540Q34115068-96178404-2095-409E-99F2-A558DB8AC4BCQ34473301-C79954C7-E9EC-44C0-9F0B-B45EE177D309Q35620945-D4E47C32-7903-408E-B477-C81710A354C9Q35647212-0F1FE931-A297-439B-A5A8-D609DBF98AF4Q35785494-55AF4D87-0C39-48CB-9DC5-124268545A96Q37240366-ACB3A9DA-FC70-4058-B9E6-4FED8AA336DAQ37388577-F9318D34-C06B-406B-A932-F97FE808CF99Q37628219-DDF81A5A-0056-4DB0-9FC6-B21B5FC3C1C4Q39205115-F8F49FBC-7177-4D04-B00E-30ED205BA3F9Q39467892-3B4B8AC6-BE37-45F1-AEE5-3FD461D45181Q39955752-01CD2EF6-9110-4971-A034-211E1A9CF734Q47559554-B1CE7708-85D2-482F-BF74-C29FDC203E4A
P2860
Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Synergy between expression of ...... otherapy in colorectal cancer.
@en
type
label
Synergy between expression of ...... otherapy in colorectal cancer.
@en
prefLabel
Synergy between expression of ...... otherapy in colorectal cancer.
@en
P2093
P2860
P356
P1433
P1476
Synergy between expression of ...... rotherapy in colorectal cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3302806
P50
P577
2006-06-22T00:00:00Z
P5875
P6179
1013895825